Intra-Cellular Therapies Inc. (NASDAQ:ITCI) shares rose 2.7% during trading on Thursday . The company traded as high as $41.80 and last traded at $41.59, with a volume of 279,961 shares. The stock had previously closed at $40.48.

Several brokerages have issued reports on ITCI. SunTrust Banks Inc. reiterated a “top pick” rating and set a $60.00 target price on shares of Intra-Cellular Therapies in a report on Tuesday, March 29th. Leerink Swann reiterated an “outperform” rating on shares of Intra-Cellular Therapies in a report on Saturday, April 16th. Cowen and Company reiterated a “buy” rating on shares of Intra-Cellular Therapies in a report on Thursday, April 28th. Zacks Investment Research cut shares of Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a report on Friday, April 29th. Finally, Piper Jaffray Cos. began coverage on shares of Intra-Cellular Therapies in a report on Wednesday, June 1st. They set an “overweight” rating and a $57.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Intra-Cellular Therapies presently has a consensus rating of “Buy” and a consensus target price of $70.78.

The company’s 50 day moving average is $39.14 and its 200-day moving average is $35.10. The stock’s market capitalization is $1.79 billion.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.14. On average, equities research analysts predict that Intra-Cellular Therapies Inc. will post ($3.14) EPS for the current year.

A number of hedge funds recently modified their holdings of the stock. Jennison Associates LLC raised its stake in shares of Intra-Cellular Therapies by 212.9% in the fourth quarter. Jennison Associates LLC now owns 1,257,846 shares of the biopharmaceutical company’s stock valued at $67,660,000 after buying an additional 855,846 shares during the period. Jennison Associates bought a new stake in shares of Intra-Cellular Therapies during the third quarter valued at about $16,096,000. California Public Employees Retirement System raised its stake in shares of Intra-Cellular Therapies by 505.4% in the fourth quarter. California Public Employees Retirement System now owns 78,700 shares of the biopharmaceutical company’s stock valued at $4,233,000 after buying an additional 65,700 shares during the period. California State Teachers Retirement System raised its stake in shares of Intra-Cellular Therapies by 24.9% in the fourth quarter. California State Teachers Retirement System now owns 49,381 shares of the biopharmaceutical company’s stock valued at $2,656,000 after buying an additional 9,852 shares during the period. Finally, New York State Common Retirement Fund raised its stake in shares of Intra-Cellular Therapies by 27.9% in the fourth quarter. New York State Common Retirement Fund now owns 26,600 shares of the biopharmaceutical company’s stock valued at $1,431,000 after buying an additional 5,800 shares during the period.

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.